These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36621810)

  • 21. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
    León-Mateos L; Mosquera J; Antón Aparicio L
    Redox Biol; 2015 Dec; 6():421-425. PubMed ID: 26386874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.
    Gupta R; Maitland ML
    Curr Hypertens Rep; 2011 Dec; 13(6):430-5. PubMed ID: 21931979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.
    Plummer C; Michael A; Shaikh G; Stewart M; Buckley L; Miles T; Ograbek A; McCormack T
    Br J Cancer; 2019 Jul; 121(2):109-116. PubMed ID: 31182765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms.
    Pantazi D; Tselepis AD
    Thromb Res; 2022 May; 213 Suppl 1():S95-S102. PubMed ID: 36210569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of hypertension in angiogenesis inhibitor-treated patients.
    Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP
    Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.
    Sundararajan S; Kumar A; Poongkunran M; Kannan A; Vogelzang NJ
    Future Oncol; 2016; 12(8):1067-80. PubMed ID: 26901457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension.
    Kruzliak P; Kovacova G; Pechanova O
    Angiogenesis; 2013 Apr; 16(2):289-95. PubMed ID: 23203441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
    Steingart RM; Bakris GL; Chen HX; Chen MH; Force T; Ivy SP; Leier CV; Liu G; Lenihan D; Lindenfeld J; Maitland ML; Remick SC; Tang WH
    Am Heart J; 2012 Feb; 163(2):156-63. PubMed ID: 22305831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab-induced hypertension: pathogenesis and management.
    Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
    BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
    Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.
    Steeghs N; Gelderblom H; Roodt JO; Christensen O; Rajagopalan P; Hovens M; Putter H; Rabelink TJ; de Koning E
    Clin Cancer Res; 2008 Jun; 14(11):3470-6. PubMed ID: 18519779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors.
    Thompson LA; Saseen JJ; O'Bryant CL; Allen RR; Nair KV
    J Oncol Pharm Pract; 2015 Aug; 21(4):258-67. PubMed ID: 24727344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
    Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment.
    Budolfsen C; Faber J; Grimm D; Krüger M; Bauer J; Wehland M; Infanger M; Magnusson NE
    Curr Vasc Pharmacol; 2019; 17(6):618-634. PubMed ID: 30706818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
    Roodhart JM; Langenberg MH; Witteveen E; Voest EE
    Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
    Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e93-e104. PubMed ID: 27755247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cardiac Dysfunction and Arterial Hypertension as Manifestations of Cardiovasculotoxicity of iVEGF-Containing Chemotherapy. Clinical Case].
    Kirichenko YY; Kulagina TY; Zhigulina OA; Ilgisonis IS; Belenkov YN
    Kardiologiia; 2024 May; 64(5):33-38. PubMed ID: 38841787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
    Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
    CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etiology of angiogenesis inhibition-related hypertension.
    Lankhorst S; Saleh L; Danser AJ; van den Meiracker AH
    Curr Opin Pharmacol; 2015 Apr; 21():7-13. PubMed ID: 25500206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.